Bio-Rad Laboratories, Inc.

As of June 30, 2026, Bio-Rad Laboratories, Inc. carries a market capitalization of 7.85B, placing it among publicly traded companies globally. Its enterprise value stands at 7.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bio-Rad Laboratories, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Bio-Rad Laboratories, Inc. has 26.74M shares outstanding.

As of June 30, 2026, Bio-Rad Laboratories, Inc. trades at a trailing price-to-earnings ratio of 35.51. The price-to-sales ratio is 3.05, and the price-to-book ratio stands at 1.09.

As of June 30, 2026, Bio-Rad Laboratories, Inc. trades at an EV/EBITDA multiple of 34.28 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.94 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 143.17 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Bio-Rad Laboratories, Inc. trades at an EV/FCF ratio of 19.79, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 7.60B versus a market cap of 7.85B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bio-Rad Laboratories, Inc. maintains a current ratio of 3.14, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.10, indicating elevated leverage, while an interest coverage ratio of 4.55 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bio-Rad Laboratories, Inc. posted a return on equity (ROE) of 3.11, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.39 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.17, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.97, useful for judging operating efficiency across full business cycles. The company generates approximately 344,665.56 in revenue per employee across its workforce of 7,512.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.58 indicates how many times Bio-Rad Laboratories, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bio-Rad Laboratories, Inc. recorded 128.00M in income tax expense. That works out to an effective tax rate of 36.53, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 350.40M, leaving 222.40M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Bio-Rad Laboratories, Inc.'s stock has gained approximately 8.84% over the past 52 weeks. The 50-day moving average sits at 372.82, while the 200-day moving average is 311.74.

Over the twelve months ended June 30, 2026, Bio-Rad Laboratories, Inc. generated 2.59B in revenue and converted that into 222.40M in net income, yielding earnings per share of 8.26. EBITDA reached 221.80M, while operating income came in at 224.50M.

As of June 30, 2026, Bio-Rad Laboratories, Inc. holds 1.62B in cash and equivalents against 1.37B in total debt, resulting in a net debt position of 686.70M. Total book value stands at 7.17B, with working capital of 2.06B providing operational flexibility.

Bio-Rad Laboratories, Inc. produced 492.60M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -139.50M in capital expenditures, free cash flow totaled 353.10M - equivalent to 13.13 per share.

Over the twelve months ended June 30, 2026, Bio-Rad Laboratories, Inc. posted a gross margin of 51.90, reflecting its pricing power and cost economics. The operating margin of 8.67 and net profit margin of 8.59 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 4.47, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.54, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bio-Rad Laboratories, Inc. shareholders.

Bio-Rad Laboratories, Inc.'s most recent stock split took place on March 8, 2002 with a 1:2 split ratio.

As of June 30, 2026, Bio-Rad Laboratories, Inc. has an Altman Z-Score of 3.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.